The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
Open accessAbstract
BACKGROUND: ER+/HER2- breast cancers have a proclivity for late recurrence. A personalised estimate of relapse risk after 5 years of endocrine treatment can improve patient selection for extended hormonal therapy. METHODS: A total of 1702 postmenopausal ER+/HER2- breast cancer patients from two adjuvant phase III trials (ABCSG6, ABCSG8) treated with 5 years of endocrine therapy participated in this study. The multigene test EndoPredict (EP) and the EPclin score (which combines EP with tumour size and nodal status) were predefined in independent training cohorts. All patients were retrospectively assigned to risk categories based on gene expression and on clinical parameters. The primary end point was distant metastasis (DM). Kaplan-Meier method and Cox regression analysis were used in an early (0-5 years) and late time interval (>5 years post diagnosis). RESULTS: EP is a significant, independent, prognostic parameter in the early and late time interval. The expression levels of proliferative and ER signalling genes contribute differentially to the underlying biology of early and late DM. The EPclin stratified 64% of patients at risk after 5 years into a low-risk subgroup with an absolute 1.8% of late DM at 10 years of follow-up. CONCLUSION: The EP test provides additional prognostic information for the identification of early and late DM beyond what can be achieved by combining the commonly used clinical parameters. The EPclin reliably identified a subgroup of patients who have an excellent long-term prognosis after 5 years of endocrine therapy. The side effects of extended therapy should be weighed against this projected outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,118
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Simon, R. M., Paik, S., & Hayes, D. F. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp335 · Cited by 1,037
Jakesz, R., Jonat, W., Gnant, M., Mittlboeck, M., Greil, R., Tausch, C., Hilfrich, J., Kwasny, W., Menzel, C., Samonigg, H., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67059-6 · Cited by 879
Self-citationAnnual hazard rates of recurrence for breast cancer after primary therapy.
Saphner, T., Tormey, D. C., & Gray, R. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2738 · Cited by 830
Nielsen, T. O., Parker, J. S., Leung, S., Voduc, D., Ebbert, M., Vickery, T., Davies, S. R., Snider, J., Stijleman, I. J., Reed, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1282 · Cited by 801
Filipits, M., Rudas, M., Jakesz, R., Dubsky, P., Fitzal, F., Singer, C. F., Dietze, O., Greil, R., Jelen, A., Sevelda, P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0926 · Cited by 733
Self-citationSgroi, D. C., Sestak, I., Cuzick, J., Zhang, Y., Schnabel, C. A., Schroeder, B., Erlander, M. G., Dunbier, A., Sidhu, K., Lopez-Knowles, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70387-5 · Cited by 399
Mamounas, E. P., Jeong, J.-H., Wickerham, D. L., Smith, R. E., Ganz, P. A., Land, S. R., Eisen, A., Fehrenbacher, L., Farrar, W. B., Atkins, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0228 · Cited by 341
Ma, X.-J., Salunga, R., Dahiya, S., Wang, W., Carney, E., Durbecq, V., Harris, A., Goss, P., Sotiriou, C., Erlander, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5026 · Cited by 315
Jakesz, R., Greil, R., Gnant, M., Schmid, M., Kwasny, W., Kubista, E., Mlineritsch, B., Tausch, C., Stierer, M., Hofbauer, F., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm246 · Cited by 312
Self-citationDubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds334 · Cited by 212
Self-citationBreast Cancer Adjuvant Therapy: Time to Consider Its Time-Dependent Effects
Jatoi, I., Anderson, W. F., Jeong, J.-H., & Redmond, C. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3550 · Cited by 172
Dubsky, P. C., Jakesz, R., Mlineritsch, B., Pöstlberger, S., Samonigg, H., Kwasny, W., Tausch, C., Stöger, H., Haider, K., Fitzal, F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8993 · Cited by 108
Self-citationKennecke, H. F., Olivotto, I. A., Speers, C. H., Norris, B. D., Chia, S., Bryce, C. J., & Gelmon, K. A. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl334 · Cited by 99
Biologic markers determine both the risk and the timing of recurrence in breast cancer
Esserman, L. J., Moore, D. H., Tsing, P., Chu, P., Yau, C. S. F., Ozanne, E. M., Chung, R., Tandon, V. J., Park, J. W., Baehner, F. L., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1564-5 · Cited by 97
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Livingston, R. B., Davidson, N. E., Perez, E. A., Chávarri-Guerra, Y., Cameron, D., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds330 · Cited by 94
Schmid, M., Jakesz, R., Samonigg, H., Kubista, E., Gnant, M., Menzel, C., Seifert, M., Haider, K., Taucher, S., Mlineritsch, B., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.138 · Cited by 65
Self-citation
Cited by
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, F., Baselga, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv221 · Cited by 1,827
Self-citation20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,822
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx308 · Cited by 1,205
Self-citation
Metadata
- Authors
- on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG), Dubsky, P., Brase, J. C., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., Bachner, M., Mayr, D., Schmidt, M., Gehrmann, M. C., Petry, C., Weber, K. E., Fisch, K., Kronenwett, R., Gnant, M., & Filipits, M.
- Venue
- British Journal of Cancer
- Published
- 2013-10-24
- Volume
- 109
- Issue
- 12
- Pages
- 2959-2964
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1980538358
- Cited by
- 350
- References
- 23
- FWCI
- 10.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.